New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer
- Details
- Category: Bayer
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the start of a Phase III study with Nexavar® (sorafenib) tablets in liver cancer. The randomized, double-blind, placebo-controlled study is evaluating Nexavar as an adjuvant therapy for patients with hepatocellular carcinoma (HCC), or primary liver cancer.
Novo Nordisk joins the Call to Action for gender equality
- Details
- Category: Novo Nordisk
Yesterday, the Danish Minister for Development Cooperation Ms Ulla Tørnæs handed over a torch to Executive Vice President Lise Kingo, Novo Nordisk, at a ceremony in Copenhagen. With the torch Ms Tørnæs makes a Call to Action to leaders from around the world to help accelerate progress on the Millennium Development Goal 3 (MDG3): To empower women and promote gender equality.
DAIICHI SANKYO continues its expansion in Germany and Europe
- Details
- Category: Daiichi Sankyo
At the beginning of August, DAIICHI SANKYO DEUTSCHLAND GmbH is planning to take over most of the sales force for primary-care physicians in Germany used by Merck Pharma GmbH and to integrate them into the existing sales structure. The agreement between the German subsidiary of the third-largest Japanese pharmaceutical group and the Darmstadt-based company will affect about 130 employees.
Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzumab, previously known as HuLuc63, currently in Phase I development for multiple myeloma.
Nycomed - strong results in second quarter 2008
- Details
- Category: Nycomed
In the first six months of 2008, Nycomedâs adjusted EBITDA increased by 4.9% to € 653.7 million compared to € 623.3 million in the first six months of 2007, benefiting from the cost decreasing effects of last yearâs restructuring and as a result of the successful integration.
Divestment of four Roche pharmaceutical products to Meda
- Details
- Category: Roche
Roche and Meda, an international specialty pharmaceutical company based in Solna (Stockholm), Sweden, have signed an agreement for the sale of four Roche pharmaceutical products to Meda. The world wide product rights for Marcoumar (Anticoagulant), Torem (Loop diuretic), Tilcotil (painful musculoskeletal disorders) and Aurorix (Depression) are being transferred to Meda for a total amount of 120 million Euros.
AstraZeneca and Abbott Expand Relationship to Include Co-Promotion of CRESTOR®
- Details
- Category: AstraZeneca
AstraZeneca and Abbott announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR® (rosuvastatin calcium), a medication used along with diet to reduce high cholesterol.
More Pharma News ...
- Teva Reports Second Quarter 2008 Results - Record Quarterly Sales of $2,823 Million
- IAFF Launches Smoking Cessation Campaign with Pfizer
- Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008
- Grindeks profit reaches 5 million lats in the first half of 2008
- PLIVA Announces H1 2008 Results
- Nycomed's preclinical anti-cancer program sold to Bayer Schering Pharma
- Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke